Embattled Intarcia drug licensed to Harvard spinout, with Intarcia CEO Kurt Graves at the helm


Years after it went silent in the wake of multiple FDA rejections, Intarcia Therapeutics is effectively back.

Previous Health Care Heroes: Non-Physician Providers from Christ Community, Methodist, Regional One, Saint Francis, St. Jude, UTHSC
Next Ruth's Chris Steak House opens on Wolf Road